newsfilter
← Earnings
Earnings Releases·

Enovis — Third Quarter 2026 Earnings Summary

  • Third-quarter net sales rose 5% organically to $559 million, with net income turning to $3 million from a prior-year loss and adjusted EBITDA expanding to $104 million (18.5% margin) from $94.8 million.
  • Full-year 2026 guidance was adjusted to raise adjusted EBITDA to $428–$438 million and EPS to $3.58–$3.79, while narrowing revenue guidance to $2.32–$2.35 billion.
  • The Board approved a new $200 million share repurchase authorization, and the company announced an agreement to acquire eCential Robotics, with strategic transaction costs for the quarter totaling $15.6 million.
  • Cash and cash equivalents declined to $13.0 million from $36.4 million at year-end 2025, while total debt stood at $1.26 billion as of October 2, 2026.
Company
ENOVIS CORP
Sector
Healthcare
Industry
Medical Devices